Institut Jules Bordet

Running trials

• Not yet recruiting

  Microwave Intervention Under Local Anesthesia

  NCT07412275· Source

• Active, not recruiting

  Holistic Evaluation of Approaches to Long-term Health & Survivorship

  NCT07745205· Source

• Recruiting

  Biopsy-Resection Agreement of Peritoneal Histopathological Growth Patterns in Colorectal Peritoneal Metastases: A Prospective Observational Pilot Study

  NCT07474025· Source

• Recruiting

  LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Radioligand THerapy.

  NCT07370597· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Source

• Recruiting

  Molecular Imaging of Cancer-associated Fibroblasts in Glioblastoma: a FAPI PET/MR Study.

  NCT07119294· Source

• Recruiting

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· Phase 2/3· Source

• Recruiting

  First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer

  NCT06934538· Phase 1/2· Source

• Recruiting

  Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume

  NCT06719440· Source

• Recruiting

  Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)

  NCT06150898· Phase 2· Source

• Recruiting

  The Role of the Imaging FAPI PET/CT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases

  NCT07109440· Source

• Recruiting

  OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)

  NCT06462963· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

  NCT06644781· Phase 3· Source

• Recruiting

  Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma

  NCT06558604· Phase 2· Source

• Recruiting

  Study on the Clinical Efficacy of Teclistamab and Talquetamab

  NCT06477783· Source

• Recruiting

  The Added-value of PSMA PET in Detecting Clinically Significant Prostate Cancer Lesions in Patients Undergoing MRI-targeted Biopsy. (PANDORA)

  NCT06867588· Source

• Recruiting

  Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

  NCT06252649· Phase 3· Source

• Active, not recruiting

  Efficacy and safety of conventional neoadjuvant therapy versus total neoadjuvant therapy in older patients with locally advanced rectal cancer: a multicentre, open-label, randomised pragmatic clinical trial

  2023-506703-26-00· Phase 3· Source

• Recruiting

  Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

  NCT05950945· Phase 3· Source

• Recruiting

  A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

  NCT06149286· Phase 3· Source

• Recruiting

  A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

  NCT06091865· Phase 3· Source

• Active, not recruiting

  A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

  NCT06097364· Phase 3· Source

• Active, not recruiting

  MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

  NCT06097728· Phase 3· Source

• Recruiting

  Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

  NCT05803941· Phase 4· Source

• Recruiting

  Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

  NCT05855200· Phase 3· Source

• Recruiting

  Molecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint Inhibitors

  NCT06107608· Source

• Recruiting

  Ga68-FAPI-46 PET/CT for Preoperative Assessment of Peritoneal Carcinomatosis

  NCT06061874· Source

• Recruiting

  Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

  NCT04954599· Phase 1/2· Source

• Recruiting

  Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma

  NCT05083247· Phase 2· Source

• Active, not recruiting

  A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

  NCT05578976· Phase 3· Source

• Recruiting

  PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.

  NCT06059469· Phase 2· Source

• Recruiting

  A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  NCT04928846· Phase 3· Source

• Active, not recruiting

  A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

  NCT04975308· Phase 3· Source

• Active, not recruiting

  Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

  NCT04821622· Phase 3· Source

• Active, not recruiting

  A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

  NCT04680052· Phase 3· Source

• Active, not recruiting

  A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

  NCT04628494· Phase 3· Source

• Active, not recruiting

  Prospective Pilot Study Evaluating Dental Side Effects of Radiotherapy on Subjects Treated for Head and Neck Cancer

  NCT04452032· Phase 2· Source

• Active, not recruiting

  Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma

  NCT04613557· Phase 1· Source

• Active, not recruiting

  Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.

  NCT04144387· Source

• Active, not recruiting

  A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

  NCT04027309· Phase 3· Source

• Recruiting

  Assessment of Swallowing Function and Quality of Life in Oropharyngeal Cancer Patients Treated by Chemo-radiotherapy

  NCT04019548· Phase 3· Source

• Active, not recruiting

  Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

  NCT04180371· Phase 1/2· Source

• Recruiting

  E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe

  NCT03818503· Source

• Active, not recruiting

  A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

  NCT03839771· Phase 3· Source

• Active, not recruiting

  Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC

  NCT03616886· Phase 1/2· Source

• Recruiting

  alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

  NCT03692429· Phase 1· Source

• Active, not recruiting

  PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases

  NCT03569241· Phase 2· Source

• Active, not recruiting

  Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

  NCT03049189· Phase 3· Source

• Active, not recruiting

  Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

  NCT02811861· Phase 3· Source

• Active, not recruiting

  Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)

  NCT02362594· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer7 recruiting
• Prostate cancer6 recruiting
• Childhood cancers4 recruiting
• Pancreatic cancer4 recruiting
• Glioblastoma2 recruiting
• Head and neck cancer2 recruiting
• Lung cancer2 recruiting
• Ovarian cancer2 recruiting
• Triple-negative breast cancer2 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and esophageal cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Neuroendocrine tumours1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  A trial to learn how effective and safe odronextamab is compared to standard of care for adult participants with previously treated aggressive B-cell Non-Hodgkin Lymphoma.

  NCT06230224· Phase 3· Source

• Completed

  (VELA) Study of BLU-222 in Advanced Solid Tumors

  NCT05252416· Phase 1/2· Source

• Recruiting

  A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06091254· Phase 3· Source

• Active, not recruiting

  A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

  NCT06045806· Phase 3· Source

• Completed

  A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA)

  2022-502057-33-00· Phase 1/2· Source

• Completed

  Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

  NCT05882734· Phase 1/2· Source

• Completed

  First-in-human phase I/IIa study investigating inhaled CIS-DPI as add-on treatment in Stage IV NSCLC patients

  2022-501183-17-00· Phase 1/2· Source

• Completed

  Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma (CLAUDIO-01)

  NCT05525286· Phase 1/2· Source

• Terminated

  Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

  NCT05289492· Phase 1· Source

• Active, not recruiting

  Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

  NCT05116189· Phase 3· Source

• Terminated

  Study of INCA 0186 in Subjects With Advanced Solid Tumors

  NCT04989387· Phase 1· Source

• Terminated

  A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

  NCT04809467· Phase 1/2· Source

• Terminated

  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

  NCT04272034· Phase 1· Source

• Completed

  Efficacy Assessment of a Novel 3D Cartography-based Targeted Focal Microwave Therapy in Men With Localized Intermediate-risk Prostate Cancer

  NCT04582656· Source

• Terminated

  Futibatinib in Patients With Specific FGFR Aberrations

  NCT04189445· Phase 2· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Source

• Completed

  Multiorgan Metabolic Imaging Response Assessment of Abemaciclib

  NCT03339843· Phase 2· Source

• Completed

  MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

  NCT03767335· Phase 1· Source

• Completed

  Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)

  NCT03674424· Phase 2· Source

• Completed

  A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

  NCT03235544· Phase 2· Source

• Completed

  A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors

  NCT03267316· Phase 1/2· Source

• Completed

  Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

  NCT03112174· Phase 3· Source

• Completed

  Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer

  NCT03127007· Phase 1/2· Source

• Completed

  Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

  NCT02007512· Phase 2· Source

• Completed

  R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

  NCT01865110· Phase 3· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

  NCT01889238· Phase 2· Source

• Completed

  A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

  NCT01740427· Phase 3· Source